Tanvex BioPharma, Inc. (TPE:6541)

Market Cap	13.07B
Revenue (ttm)	81.18M
Net Income (ttm)	-1.43B
Shares Out	238.49M
EPS (ttm)	-8.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,201,815
Average Volume	822,967
Open	52.30
Previous Close	52.50
Day's Range	51.70 - 55.50
52-Week Range	48.10 - 82.00
Beta	0.02
RSI	58.42
Earnings Date	Aug 8, 2025

About Tanvex BioPharma

Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 198
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6541

Financial Performance

In 2024, Tanvex BioPharma's revenue was 34.68 million, a decrease of -43.53% compared to the previous year's 61.41 million. Losses were -1.38 billion, -35.35% less than in 2023.